Spanish researchers who looked at data on 15 5- to 17-year-olds with refractory uveitis found that 86% experienced an initial improvement in inflammation activity following adalimumab therapy. The treatment was effective in 60% of patients with juvenile idiopathic arthritis-related refractory uveitis and mildly effective in 13%. However, the study in the Journal of the American Association for Pediatric Ophthalmology and Strabismus showed that the effectiveness of the treatment waned over time.

Full Story:

Related Summaries